Fate Therapeutics, Inc. [FATE] is following upward trend in the market concluded with the last trading session. The shares of the Healthcare sector company has a current value of $13.67 after FATE shares went up by 0.74% during the last trading session. One of the reasons why Healthcare stocks may go bullish is increased momentum in the press.
Fate Therapeutics, Inc. [NASDAQ:FATE]: Analyst Rating and Earnings
Its stock price has been found in the range of 11.00 to 22.82. This is compared to its latest closing price of $13.57.
Keep on the lookout for this organization’s next scheduled financial results, which are expected to be made public on Tue 3 Mar (In 86 Days).
Fundamental Analysis of Fate Therapeutics, Inc. [FATE]
Now let’s turn to look at profitability: with a current Operating Margin for Fate Therapeutics, Inc. [FATE] sitting at -1415.44.
This company’s Return on Total Capital is -50.19, and its Return on Invested Capital has reached -38.30%. Its Return on Equity is -56.05, and its Return on Assets is -41.84. These metrics suggest that this Fate Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Fate Therapeutics, Inc. [FATE] has generated a Total Debt to Total Equity ratio of 9.28. Similarly, its Total Debt to Total Capital is 8.49, while its Total Debt to Total Assets stands at 6.99. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -39.56, and its Long-Term Debt to Total Capital is 7.76.
What about valuation? This company’s Enterprise Value to EBITDA is -12.86. The Enterprise Value to Sales for this firm is now 88.82, and its Total Debt to Enterprise Value stands at 0.03. Fate Therapeutics, Inc. [FATE] has a Price to Book Ratio of 5.17.
Shifting the focus to workforce efficiency, Fate Therapeutics, Inc. [FATE] earns $45,577 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 18.96 and its Total Asset Turnover is 0.03. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 7.53 and its Current Ratio is 7.53. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Fate Therapeutics, Inc. [FATE] has 75.04M shares outstanding, amounting to a total market cap of $1.03B. Its stock price has been found in the range of 11.00 to 22.82. At its current price, it has moved down by -40.10% from its 52-week high, and it has moved up 24.27% from its 52-week low.
This stock’s Beta value is currently 1.93, which indicates that it is 6.47% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 42.93. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Fate Therapeutics, Inc. [FATE] a Reliable Buy?
Shares of Fate Therapeutics, Inc. [FATE], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.